Skip to main content

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.


Investor Contact:

Priyam Shah
investors@akoyabio.com

Media Contact:

Christine Quern
media@akoyabio.com

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.27
-4.84 (-2.30%)
AAPL  266.18
+1.60 (0.60%)
AMD  196.60
-3.55 (-1.77%)
BAC  51.07
-1.99 (-3.75%)
GOOG  311.69
-3.21 (-1.02%)
META  637.46
-18.20 (-2.78%)
MSFT  384.47
-12.76 (-3.21%)
NVDA  191.55
+1.73 (0.91%)
ORCL  141.31
-6.77 (-4.57%)
TSLA  399.83
-11.99 (-2.91%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.